Compare Howmet Aerospace Inc (HWM) vs Tango Therapeutics Inc. (TNGX) Price & Performance

Howmet Aerospace (HWM) trades at $216.84, down 1.8% with bearish technical signals despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters with Q2 2026 EPS of $1.33 exceeding expectations. Revenue growth continues with 2026 projections showing $9.1B revenue and 20.52% net margin. Analyst consensus remains strongly bullish with 84% buy ratings and $328.10 price target representing 51% upside potential.

The stock presents compelling growth potential driven by aerospace demand and defense modernization trends, though technical weakness and valuation concerns at 46.7x P/E warrant caution. Strong cash flow generation supports shareholder returns including dividends and buybacks, while supply chain risks and competitive pressures remain key watchpoints for investors.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.